CG Oncology, Inc. Cash and Restricted Cash
CG Oncology, Inc. (CGON) had Cash and Restricted Cash of $19.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.64M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $33.70M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32.49M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.15M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $19.64M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $33.70M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $32.49M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $45.15M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $14.62M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $41.47M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $257.07M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $43.41M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $25.16M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $77.47M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $8.27M 10-K · filed 2026-02-27 |
| 2023-09-30 | $10.27M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $78.04M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $693.00K 10-Q · filed 2024-05-09 |
| 2022-12-31 | $88.14M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |